Table 7

Landmark analysis of survival with imatinib versus other therapies by the degree of cytogenetic response at 3 and 6 months

Estimated 3-year survival from start of therapy (%)
ImatinibOther
No.3-yr survival (%)No.3-yr survival (%)P
Cytogenetic response at 3 months
Major1159834800.01
Minor319210600.04
Other11484104540.0008
Cytogenetic response at 6 months
Major1069733820.07
Minor271007860.27
Other848572570.01